Table 1.
Demographic and Clinical Characteristics for Patients With and Without Chemotherapy-Related Hospitalizationa
| Characteristic | Cases (n = 146) |
Controls (n = 292) |
OR (95% CI)b | P Value |
|---|---|---|---|---|
| Age, median, y | 68 | 67 | 1.00 (0.98–1.01) | .55 |
| Sex | ||||
| Female | 79 (54) | 157 (54) | 1 [Reference] | .95 |
| Male | 67 (46) | 135 (46) | 1.01 (0.68–1.51) | |
| ECOG performance status | ||||
| 0 | 28 (19) | 74 (25) | 1 [Reference] | .23 |
| 1 | 87 (60) | 174 (60) | 1.37 (0.83–2.27) | |
| ≥2 | 31 (21) | 44 (15) | 1.74 (0.92–3.30) | |
| Charlson comorbidity scorec | ||||
| 0 | 44 (30) | 137 (51) | 1 [Reference] | <.001 |
| 1 | 33 (23) | 55 (21) | 1.87 (1.08–3.24) | |
| ≥2 | 69 (47) | 76 (28) | 2.83 (1.77–4.53) | |
| Primary cancer site | ||||
| Lung | 49 (34) | 110 (38) | 1 [Reference] | .13 |
| Gastrointestinal | 47 (32) | 65 (22) | 1.62 (0.98–2.69) | |
| Breast | 16 (11) | 39 (13) | 0.92 (0.47–1.80) | |
| Genitourinary | 7 (5) | 25 (9) | 0.63 (0.26–1.55) | |
| Gynecological | 7 (5) | 25 (9) | 0.63 (0.26–1.55) | |
| Head and neck | 9 (6) | 11 (4) | 1.84 (0.72–4.72) | |
| Other | 11 (8) | 17 (6) | 1.45 (0.63–3.33) | |
| BMI | ||||
| <18.5 | 10 (7) | 18 (6) | 1.24 (0.54–2.88) | .44 |
| 18.5–24.9 | 51 (35) | 114 (40) | 1 [Reference] | |
| 25.0–29.9 | 54 (37) | 85 (30) | 1.42 (0.88–2.28) | |
| ≥30 | 31 (21) | 70 (24) | 0.99 (0.58–1.69) | |
| Chemotherapy drugs, No | ||||
| Monotherapy | 42 (29) | 129 (44) | 1 [Reference] | .002 |
| Polytherapy | 104 (71) | 163 (56) | 1.96 (1.28–3.00) | |
| Chemotherapy regimen dosing | ||||
| Full | 108 (74) | 229 (80) | 1 [Reference] | .19 |
| Reduced | 37 (26) | 57 (20) | 1.38 (0.86–2.21) | |
| Chemotherapy classd | ||||
| Platinum | 87 (60) | 135 (46) | 1.71 (1.15–2.57) | .01 |
| Taxane | 43 (29) | 95 (33) | 0.87 (0.56–1.33) | .51 |
| Fluoropyrimidine | 39 (27) | 53 (18) | 1.64 (1.03–2.64) | .04 |
| Camptothecin | 18 (12) | 21 (7) | 1.81 (0.93–3.52) | .08 |
| Gemcitabine | 17 (12) | 31 (11) | 1.11 (0.59–2.08) | .75 |
Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ECOG, Eastern Cooperative Oncology Group7; OR, odds ratio.
a
Unless otherwise noted, data are number (percentage) of patients.
b
Univariate analysis.
c
No points were assigned for metastatic cancer.
d
Column percentages exceed 100% because patients could receive agents from multiple classes concurrently.